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1. Introduction 
Cancer is a pro-inflammatory disease. The link between inflammation and cancer was first 
noticed over 150 years ago. In 1863, Virchow observed that tumours tend to occur at sites of 
chronic inflammation (Balkwill, 2001).   
Epidemiological studies have recently emerged which support the association between 
cancer and inflammation. Viruses and bacteria cause chronic inflammation and are 
significant risk factors in the development of malignancy. Human papilloma viruses, 
hepatitis B, hepatitis C and helicobacter pylori are well studied examples of this 
phenomenon which result in cervical cancer, hepatocellular cancer, lympho-proliferative 
disorders and gastric cancer respectively. Furthermore, increased risk of malignancy is 
associated with chronic inflammation caused by chemical and physical agents (Gulumian, 
1999). In addition to epidemiological data, gene-cluster polymorphisms that lead to 
increased levels of pro-inflammatory cytokine release are associated with a poorer prognosis 
and disease severity in cancer patients (Warzocha, 1998;  El-Omar, 2000). Moreover, the fact 
that chronic use of NSAIDs, such as aspirin are shown to reduce the incidence of numerous 
cancer types including colon, lung and stomach, gives additional supporting evidence for 
the link between inflammation and cancer (Wang, 2003). 
2. NF-κB – A key player 
Recent studies have implicated an inflammation-induced protein called nuclear factor 
kappa B (NF-κB) as a central figure in the link between cancer and inflammation. In 1986, 
Baltimore et al., originally discovered NF- κB as a factor in the nucleus of B cells that binds 
to the enhancer of the kappa light chain of immunoglobulin (Sen, 1986). NF- κB activity is 
considered a hallmark of inflammation. It is shown that NF-κB manipulation can convert 
inflammation-driven tumour growth into inflammation-induced tumour regression (Luo, 
2004). Furthermore, many oncogenes and carcinogens can cause activation of NF-κB, 
whereas chemicals with chemo-protective properties can interfere with NF-κB activation 
(Bharti, 2002). 
In unstimulated cells, the majority of NF-κB complexes are kept predominantly cytoplasmic 
and in an inactive form by binding  a family of inhibitors known as Inhibitor-κB (IκB). The 
NF-κB pathway can be activated by numerous stimuli including bacteria, viruses and pro-
inflammatory cytokines especially tumour necrosis factor (TNF). Phosphorylation of NF-κB 
bound I-kappa-B kinases (IκK) on two conserved serine residues within the N-terminal 
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domain of the IκB proteins, which allows for proteasomal degradation and resultant NF-κB 
liberation. Activation of the NF-κB signalling cascade results in complete degradation of IκB 
allowing translocation of NF-κB to the nucleus where it induces transcription. The NF-κB 
family of transcription factors is composed of homodimers and heterodimers derived from 5 
subunits - including REL-A(p65), c-REL, REL-B, p50(NF-κB1) and p52 (NF-κB2). When these 
subunits enter the nucleus, they can mediate transcription of target genes (Hayden, 2004). 
All family members share a highly conserved Rel homology domain responsible for DNA 
binding, dimerization domain and interaction with IκBs, the intracellular inhibitor of NF-κB.  
Cellular stresses including ionising radiation and chemotherapeutic agents can also activate 
NF-kB. The subsequent release of pro-inflammatory mediators (CSF-1, COX-2, IL-6, IL-1, 
VEGF, TNF) (Luo, 2004; Marx, 2004) and known anti-apoptotic regulators (BCL-2 and 
GADD45ǃ) are thought to potentiate tumour growth. In 2004, Karin et al discovered the 
mechanism that NF-κB contributes to tumourigenesis (Luo, 2004). Prior to this study 
evidence implicating NF-κB and cancer was mostly circumstantial. Using a murine model of 
colitis-associated cancer, researchers were able to use genetically altered mice which had the 
NF-κB activator enzyme IκK knocked out of intestinal epithelial cells and macrophages. In 
the absence of the IκK gene, neither cell could activate NF-κB. Interestingly, loss of NF-κB 
activity in both macrophages and epithelial cells individually reduced tumour incidence. 
They also found that this occurred through two different mechanisms. Tumour incidence 
decreased by approximately 50% with the loss of NF-κB activity in macrophages through a 
reduction in growth factors produced by inflammatory cells normally induced by NF-κB 
activation. Secondly, the loss of NF-κB activity in intestinal epithelial cells resulted in an 
80% drop in tumour incidence. The mechanism seen here was different to that seen with the 
macrophages. Inflammation was not reduced as with the macrophages, instead, apoptosis 
was no longer inhibited in intestinal cells (Karin, 2004). Pikarsky et al had similar findings in 
a murine model of inflammation-associated liver cancer where they inhibited NF-κB by 
adding a gene encoding for IκB, a natural NF-κB inhibitor (Pikarsky, 2004). 
The NF-κB family of transcription factors plays a key role in regulation of immune and 
inflammatory responses including apoptosis and oncogenesis (Baldwin, 2001). NF-κB 
regulated gene products including those encoding ICAM-1, the extracellular matrix protein 
tenascin C, vascular endothelial growth factor (VEGF), the chemokine IL-8, the pro-
inflammatory enzyme COX2 and matrix metalloprotease 9 (MMP9) are associated with 
tumour progression and metastasis (Karin, 2002). However NF-κB may also control the 
expression of apoptosis promoting cytokines such as TNF alpha and FAS ligand (Kasibhatla, 
1998).  
NF-κB activation is required for endotoxin induced tumour growth. Lou et al showed both 
tumour nodule numbers and lung weights in the Lipopolysaccharide (LPS) challenged CT26 
and CT26 vector groups were significantly higher than the controls (<0.05) (Luo, 2004). This 
demonstrates that inhibition of NF-κB activity in cancer cells converts the LPS-induced 
proliferative response to an apoptotic response. LPS was shown to induce NF-κB dependent 
genes in tumour cells. TNF alpha was shown to mediate LPS induced tumour growth and 
NF-κB activation. TRAIL mediates LPS induced regression of NF-κB deficient tumours. 
Overall, NF-κB in CT26 cells is responsible for induction of several anti-apoptotic proteins 
including Bcl-2 and Bcl-X. Most importantly the inhibition of NF-κB converted the growth 
promoting effect of LPS mediated by TNF alpha into a cytocidal effect. Trail is a weak 
inducer of inflammation which is an important characteristic, most likely related to its poor 
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NF-κB activating ability. In addition to preventing the expression of anti-apoptotic proteins, 
inhibition of NF-κB also led to increased expression of the Trail receptor DR5. Type I and II 
interferons (IFN) are efficient inducers of Trail. The authors postulate that IFN based 
therapy with anti-TNF alpha medications may reduce inflammation associated toxicities, 
block inflammation induced tumour growth and potentiate Trail dependent tumour killing. 
The bcl-2 family of proto-oncogenes are a critical regulator of apoptosis and are frequently 
deregulated in a wide variety of cancers. They have recently been identified as having an 
NF-κB binding site in the bcl-2 p2 promoter (Catz, 2001).  Thus chemotherapeutic drugs that 
activate NF-κB can also activate bcl-2 family proteins in various cancer cell lines. Activated 
NF-κB binds to specific DNA sequences in target genes, designated as kB elements and 
regulates transcription of over 400 genes involved in immunoregulation, growth, 
inflammation, carcinogenesis and apoptosis.  
Several chemotherapeutic agents including 5-fluorouracil (5-FU) have been reported to 
induce NF-κB activation in various cell lines (Cusack, 1999). Cytotoxic drugs induce NF-κB 
with delayed kinetics. This delay is due to the time required to induce nuclear DNA damage 
and relay the damage signal to the cytoplasmic IκK complex. Treatment with 5-FU can also 
induce activation of NF-κB in colorectal cancer cells (Wang, 2003). Using RKO human 
colorectal cell line and two NF-κB signalling deficient RKO mutants, Fukuyama et al 
demonstrated that 5-FU stimulates NF-κB and RKO cell survival through induction of IκK 
activity (Fukuyama, 2007). Several studies have shown that inhibition of NF-κB activation 
results in reversal of chemoresistance (Jones, 2000; Arlt, 2001; Cusack, 2001). It was shown 
that the inhibition of inducible NF-κB by a NF-κB decoy could induce apoptosis and reduce 
chemoresistance against 5-FU (Uetsuka, 2003). Inhibition of NF-κB activity reduces chemo-
resistance to 5-fluorouracil (5-FU) in human stomach cancer. Ionising radiation (IR) has been 
reported to activate NF-κB in both in vitro and in vivo studies (Rithidech, 2005; Ahmed, 
2006). Laszlo et al recently reported that IkB-alpha depletion in the late phase of IR is a 
result of a combined regulation at both transcription and translation levels (Laszlo, 2008).  
3. Toll-like receptors 
3.1 Overview 
Inflammation is initiated through many cellular transmembrane receptors of which the best 
characterised are the TLR family. Toll like receptors (TLRs) have been the subject of 
extensive investigation since their discovery in 1996. The first Toll receptor was discovered 
in Drosophila and it was revealed that the innate immune system may be activated once the 
receptor was bound by an extracellular ligand (Belvin, 1996). Subsequent research has 
revealed a total of 13 mammalian TLRs, 11 of which are expressed in humans. They are 
involved in the recognition by immune and non-immune cells of stimuli such as 
lipopolysaccharides (LPS) and dsRNA. They signal through the use of adapter proteins such 
as TRIF-related adaptor molecule (TRAF) and myeloid differentiation factor 88 (Myd88) 
(Killeen, 2009). Recognition of pathogen–associated molecular patterns (PAMPS) through 
TLRs, either alone or in heterodimerization with other TLRs or non-TLRs, triggers signals 
responsible for activation of the innate and adaptive immune responses. Most TLRs are 
found in innate immune cells such as polymorphonuclear neutrophils, 
monocytes/macrophages and dendritic cells where they trigger an immediate response. 
More recently TLRs have been shown to be expressed in a number of different cancer cells 
(Cheadle, 2002; Huang, 2008). Recent experimental evidence shows that TLRs display both 
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tumouricidal and tumourigenesis properties (Salaun, 2006; Killeen, 2008). Each TLR 
recognises a different ligand. All TLRs (except for TLR3) signal through the adapter protein 
MyD88. MyD88 has been found to play a key role in inflammation induced tumour growth, 
principally through the innate immune system (Rakoff-Nahoum S, 2007). MyD88 mediates 
NF-κB activation through the canonical pathway (O'Neill, 2008; Akira, 2006). MyD88 is 
capable of NF-κB signalling selectively via TLR2 (Fitzgerald, 2003; Horng, 2001). Hence, 
both TLR2 and TLR4 both of which are expressed on the plasma membrane of cells appear 
to be involved in NF-κB inflammation-associated tumourigenesis. TLR2 is stimulated by 
numerous pro-inflammatory stimuli and helps activate the innate immune system.     
Several TLRs are responsible for NF-κB activation. TLR4 induces tumour growth through 
NF-κB activation mediated by TNF- (Luo, 2004). Interestingly, endotoxin or LPS, which 
binds specifically to TLR4 in cells is shown to be capable of inducing tumour growth 
(Pigeon, 1999). Endotoxin is a molecule found in the outer membrane of Gram-negative 
bacteria and elicits a strong inflammatory response in animals. Hence, it appears that the 
pro-tumorigenic effects of endotoxin occur through TLR4 mediated NF-κB activation.  The 
focus of recent cancer immunology and medical oncology research has been aimed at 
activating the immune system in order to inhibit cancer cell growth and induce cancer cell 
apoptosis. Thus, TLRs offer a unique target for cancer therapy. 
3.2 Toll-like receptor-3 
TLR3 is a type 1 trans-membrane receptor protein located intracellularly on the endosome of 
eukaryotic cells. TLR3 has been shown to be an important “danger” signalling receptor that 
has a dual role in controlling the delicate balance between tolerance and inflammation on 
one hand and inflammation and disease on the other hand (Vercammen, 2008). TLR3 is 
composed of an ectodomain (ECD) containing multiple leucine rich repeats (LRRs), a 
transmembrane region and a cytoplasmic tail containing the Toll interleukin-1 receptor 
(TIR) domain (Vercammen, 2008). The LRRs form a horse shoe shaped solenoid structure 
which is capped at one end by a LRR N-terminal (LRR-NT) and at the other end by a LRR C-
terminal (LRR-CT) (Bell, 2005). The TLR3 ectodomain (ECD) binds dsRNA. This can only 
occur in an acidic environment (pH<6.5) reflecting the endosomal location of the receptor. 
DsRNA binding initiates a signalling pathway that recruits the TIR domain containing 
adaptor protein (TRIF) to its cytoplasmic domain. TLR3 is the sole TLR to interact directly 
with TRIF.  The TIr domain of TLR3 then binds to TRIF. This indirectly activates several 
transcription factors including NFκB and IRF3. TRIF knockout mice have shown impaired 
Interferon-B production in response to a TLR3 ligand which proves that TRIF is essential to 
the signalling pathway (Takeuchi, 2003). TRIF is an adaptor molecule which is essential for 
TLR-3 signalling pathways (Yamamoto, 2003). The activity of TRIF allows indirect activation 
of several transcription factors such as NF-κB and IRF-3.  
TLR3 is the critical sensor of the dsRNA. In response to dsRNA stimulation, specific 
signalling pathways are activated leading to activation of transcription factors such as 
nuclear factor- κB (NF-κB) and interferon regulatory factor 3 (IRF-3). This response acts as a 
defence mechanism against a viral insult to the body. The dsRNA itself is produced during 
viral replication (Jacobs, 1996). Strong or sustained TLR-3 signalling is potentially harmful 
and in some cases fatal to the host cell. It appears that the mammalian cells have adapted to 
this using a negative feedback mechanism. PIK3 and RIP-1 binding to TRIF has been shown 
to inhibit the actions of TRIF signalling (Meylan, 2004). Polyribosinic:polyriboctidic acid 
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(poly I:C) is a stable synthetic dsRNA which acts as an agonist on the TLR3 receptor. It has 
been the subject of anti-cancer immunotherapy trials for decades. However its activity on 
the TLR3 receptor as well as RIG-1 and MDA-5 has only been recently identified. It activates 
the human innate system which subsequently regulates adaptive immunity. Poly I:C is 
recognised by both endosomal receptor TLR3 and cytosolic receptors including RNA 
helicases such as RIG-1 melanoma differentiation associated gene 5 (MDA5). TLR3 
preferentially recognizes synthetic poly(I:C) rather than a virus derived dsRNA (Okahira, 
2005). The important role played by TLR3 in poly I:C recognition was shown in one study 
which used TLR3 deficient mice. These mice demonstrated reduced responses to poly I:C 
and produced lower levels of inflammatory cytokines (Alexopoulou, 2001). Poly I:C has 
several side effects such as nephrotoxicity, coagulopathies and hypersensitivity reactions. In 
order to reduce this toxicity a modified form of poly I:C known as Poly I:C12U  has been 
produced. This substitutes uridine for cytosine at a ratio of 1:12 and results of a clinical trial 
of patients with HIV have proven Poly I:C12u to be very safe. Studies using differing lengths 
of poly I:C showed that longer duplexes are better inducers of TLR3 signalling (Boone, 2004; 
Okahira, 2005). There are various alternatives to Poly I:C available. Poly I:C12U is a 
mismatched dsRNA helix in which uridine has replaced cytosine. It has a rapid half-life 
compared to Poly I:C which has opened the door for its use as a clinically useful drug. Poly 
I:C12U  is more specific in its binding to TLR3 and this may account for its reduced toxicity 
and safe use in clinical trials (Mitchell, 2006). No evidence exists of dose limiting organ 
toxicity including haematological, liver or renal toxicity following intravenous 
administration to HIV positive patients (Thompson, 1996). Poly I:C mediates a potent 
adjuvant effect in cells expressing TLR3 and this strongly enhances antigen specific CD8+ T-
cell responses, promotes antigen cross presentation by dendritic cells (Cui, 2006; Schulz, 
2005) and directly acts on effector CD8+ T and natural killer cells to alter the release of IFN-Ǆ 
(Tabiasco, 2006). It is the most potent type 1 interferon stimulant that is recognised by TLR3 
(Yoneyama, 2004; Matsumoto, 2008). 
TLR3 stimulation by dsRNA can cause direct apoptosis and inhibit cell proliferation in 
various types of cancer cells including colon, breast and melanoma (Taura, 2010; Salaun, 
2006, 2007). It is now known that expression and function of TLR3 is dependent on p53 
activation (Taura, 2008). Salaun et al recently used poly I:C to treat a breast cancer cell line 
by triggering apoptosis (Salaun, 2006). They showed that poly I:C can directly cause 
apoptosis without the involvement of the immune system. They also showed that poly I:C 
induced apoptosis occurred through the Fas-associated protein death domain-caspase 8 
signalling pathway. The extrinsic apoptotic pathway was also shown to be involved by the 
same group in selected cancer cells (Salaun, 2007). Polyadenylic:polyuridylic acid (poly A:U) 
is another synthetic double stranded RNA. Poly A:U is unique as it only signals through 
TLR3. Poly A:U has been used with moderate success to treat breast and gastric cancer as a 
monotherapy (Laplanche, 2000; Jeung, 2010). Interferons (IFN) are a group of cytokines that 
can cause antiviral, antiproliferative and apoptotic effects through the Jak/STAT pathway 
signal transducers (Stark, 2007). In particular, IFN-ǂ, a type I IFN has been shown to induce 
TLR3 expression and thus significantly enhance tumour cell apoptosis when combined with 
Poly I:C compared to each treatment alone (Taura 2010). The same study combined IFN-ǂ, 
Poly I:C and 5-FU which resulted in a significant increase in cancer cell death in a colon 
cancer cell line. They also showed that by inhibiting the JAK/STAT pathway, induction of 
TLR3 by INF- ǂ caused a reduced response of TLR3 to INF- ǂ stimulation. Several clinical 
trials have examined the effect of combining a TLR3 agonist and INF-ǂ with or without a 
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chemotherapeutic agent. Wadler et al combined 5-FU with INF-ǂ and achieved a good 
response in colon cancer cells however this combination was not effective in clinical trials 
(Wadler, 1990). Early clinical trials involving a TLR3 agonist as a single adjuvant therapy in 
colorectal cancer showed mixed results. Lacour et al showed that Poly A:U alone as an 
adjuvant therapy in colorectal cancer patients who had undergone a resection of the 
primary tumour was unable to improve the overall survival of patients after five years 
compared to a placebo (Lacour, 1992). However, when used as a combination therapy there 
have been very positive results in a clinical trial to demonstrate a positive role for Poly A:U 
in cancer treatment. After a 14 year median follow-up Laplanche et al reported the results of 
a trial which combined Poly A:U with loco-regional radiotherapy versus chemotherapy with 
cyclophosphamide, methotrexate and fluorouracil (CMF) in women with operable breast 
cancer. They reported that the Poly A:U combination group had a significantly improved 
disease free survival (p=0.03) and significantly reduced the incidence of metastasis when 
compared to the CMF group. This trial did not however differentiate the role that Poly A:U 
and radiotherapy had as single therapies (Laplanche, 2000). Several studies have reported 
that caspase 3 is up-regulated by TLR3 agonist activity which would suggest a role for 
caspase 3 in cancer cell apoptosis induced by TLR3 agonists (Salaun, 2006; Khvalevsky, 
2007). A recent study by Conforti et al demonstrated the synergistic effects between 
vaccines, chemotherapy and poly A:U (Conforti, 2010). A vaccine (OVA plus CpG) was 
administered prior to the combination of oxaliplatin and poly A:U and this significantly 
reduced tumour growth and prolonged survival. Interestingly these results were not 
demonstrated in nude and TRIF knockout mice. 
3.3 Toll-like receptor-4 
TLR4 was first discovered in 1998. Lipopolysaccharide (LPS) is a cell wall protein in gram 
negative bacteria and works as a ligand for TLR4. The recognition of LPS by TLR4 requires 
other proteins including LPS binding protein, CD14 and MD2. In resting cells TLR4 is 
located in the Golgi apparatus. The translocation of TLR4 from the Golgi apparatus to the 
plasma membrane and the binding of LPS is dependent on MD2 (Nagai, 2002; Shimazu, 
1999). TLR4 signals through two pathways: the MyD88-dependant pathway and the 
MyD88-independant pathway. In the MyD88-dependant pathway, MyD88 binds to the Toll-
IL-1 receptor domain of the TLR4 receptor and activates IL-1 receptor associated kinase 
(IRAK). IRAK in turn phosphorylates TRAF6, which in turn activates a MAP-3-kinase called 
TAK1, and TAK1 phosphorylates and activates the IκK complex. IκK then liberates NFκB. 
Killeen et al showed that bacterial endotoxins directly promote tumour cell adhesion and 
invasion through up-regulation of urokinase plasminogen activator and urokinase 
plasminogen activator receptor through TLR4 dependant activation of NFKB (Killeen 2009). 
TLR4 can also signal through the MyD88-independant pathway to stimulate the production 
of Interferon-B. Wang et al showed that TLR4/MyD88 over-expression was frequently 
detected in colo-rectal cancer with liver metastasis and TLR4/MyD88 levels were 
significantly higher in these patients (Wang, 2010). Although there have been a number of 
studies investigating the role of TLR4 in colo-rectal cancer, the exact impact of TLR4 
signalling in comparison to TLR3 signalling in colon cancer cells has yet to be established. 
TLR4 signalling has been shown to promote resistance of cancer cells to apoptosis following 
introduction of a TLR4 ligand in colon cancer cells (Cianchi, 2010). TLR4 signalling appears 
to promote the development of colitis associated cancer by mechanisms including enhanced 
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Cox-2 expression and increased EGFR signalling (Fukata, 2007). Recent experimental studies 
have shown that TLR4 induced inflammatory factors may cause tumour cell escape from 
immune surveillance and resistance to chemotherapy and radiotherapy (He, 2007).   
One proposed mechanism by which tumour cells resist treatment involves an impairment of 
the immune response by the inflammatory microenvironment at the tumour site (Coussens, 
2002). TLR4 upregulation has been shown to increase the secretion of immunosuppressive 
cytokines TGF-ǃ, VEGF and pro-angiogenic chemokine IL-8 in human lung cancer cells and 
induces resistance of human lung cancer cells to TNF-ǂ and TRAIL induced apoptosis (He, 
2007). The same study demonstrated secretion of VEGF and IL-8 is p38MAPK dependent 
and the ERK1/2 and JNK1/2 proteins are not activated. NF-κB activation contributes to 
apoptosis resistance of human lung cancer cells after LPS stimulation and LPS-induced 
apoptosis is dependent on NF-κB activation in human lung cancer cells. NF-κB is an anti-
apoptotic transcriptional factor induced by cellular components such as LPS, radiation and 
various chemotherapy drugs. 
Contrasting evidence for the role of TLR4 in chemotherapy and radiotherapy resistance was 
reported by Apetoh et al who demonstrated reduced tumour growth and prolonged 
survival in immunocompetent wild type mice when treated with chemotherapeutic agents 
such as oxaliplatin and doxorubicin but this effect was significantly less in TLR4-/- mice and 
nu/nu mice (Apetoh, 2007). These findings were also demonstrated in TRIF-/- mice which 
behaved like the wild type mice but Myd88-/- mice behaved like TLR-/- mice. This suggests a 
certain dependence of tumour treatment resistance on the MyD88 dependent pathway in 
TLR4 signalling. These results show that when TLR4 itself is knocked out this will lead to a 
reduction in tumour growth when the tumour is exposed to an appropriate 
chemotherapeutic agent or radiotherapy. However, when TLR4 is up regulated in the 
presence of LPS, this results in resistance to chemotherapy and arguably radiotherapy 
treatment. 
Various agents have been suggested as having a role in reversing TLR4 induced tumour 
apoptotic resistance. Rapamycin is one such agent. Rapamycin is a macrolide antifungal 
agent and is a potent immunosuppressive medication that is used as an anti-inflammatory 
and immunosuppressive drug for the treatment of autoimmune diseases such as Systemic 
lupus erythematosus (SLE) and transplantation rejection (Fernandez, 2006; Hackstein, 2003). 
In terms of cancer treatment Rapamycin has been shown to display a number of useful anti-
cancer cell properties including inhibition of cancer cell proliferation and induction of 
apoptosis (Hartford, 2007; Zhang, 2007). Rapamycin can also inhibit invasion and metastasis 
of tumour cells (Abraham, 2007). One study focused on Rapamycins ability to reverse the 
apoptotic resistance that can occur following TLR4 stimulation with LPS. Sun et al showed 
that Rapamycin reverses TLR4 ligation induced apoptotic resistance in colon cancer cells 
(Sun, 2008). Interestingly this same study showed that Rapamycin inhibits anti-apoptotic 
protein bcl-xL expression and activation of Akt and NF-κB pathways following LPS 
treatment of cells and this was shown to reverse apoptosis when Akt and NF- κB were 
inhibited. Paclitaxel has been described as a potential ligand to TLR4 (Asselin, 2001). Kelly et 
al demonstrated that TLR4 signalling promotes tumour growth and paclitaxel chemo-
resistance in ovarian cancer cells (Kelly, 2006). This behaviour was mediated by MyD88 
expression. 
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4. Role of chemokines and cytokines 
4.1 Overview 
Both TLR3 and TLR4 signalling produce a pro-inflammatory response including 
chemokines and it has previously been shown that the pro-inflammatory response may 
contribute to tumorigenesis (Kelly, 2006). Chemokines and cytokines are markers of 
inflammation which normally recruit leucocytes and aid in blood vessel remodelling. 
Pathophysiological roles for chemokines include acting as autocrine growth factors, 
disruption of basement membranes, increasing motility and tumour invasion (Rollins, 2006; 
Balkwill 2004).  
4.2 CXCL-8/IL-8 
A recent paper examined the presence of cytokines, chemokines and their receptors in colon 
cancer using a Taqman Low Density Array with probes for 24 ligands and 17 receptors. This 
revealed CCL3, CCL4 and CXCL8 levels to be significantly increased in colon cancer 
samples compared to normal tissue (Erreni, 2009). Further analysis of the levels of CCL3, 
CCL4 and CXCL8 mRNA expression showed that CCL4 and CCL3 levels were higher in 
normal and tumour tissue. However, CXCL8 expression was significantly increased in 
tumour tissue (p<0.0001). There was no correlation with tumour stage for all three 
inflammatory markers. SW620 and HT29 cell lines showed low but detectable levels of 
CXCL8 which increased with stimulation with TNFǂ and TGFǃ. Interestingly there was 
high levels of two anti-angiogenic chemokines found in these samples also, CXCL9 and 
CXCL10 but their receptor was not significantly expressed. 
The main function of CXCL8 is the recruitment of neutrophils. These leucocytes have a short 
life span and have no presence or role in the tumour micro-environment. CXCL8 has 
however been reported to have a role in the tumour micro-environment by stimulating 
tumour advancement and invasion by stimulating the process of neoangiogenesis and by 
activating tumour matrix proteases (Zhu, 2004; Bates, 2004). However, CCL3 and CCL4 are 
not products of TLR3 and TLR4 signalling, but CXCL8 is produced as a result of signalling 
by TLR3 and TLR4. Elevated levels of CXCL8 or Interleukin-8 has been associated with 
increased angiogenesis in normal and transformed tissue adjacent to colon cancer tumours 
(Fox, 1998; Kuniyasi, 2000). Also, increased CXCL8 protein expression in primary colo-rectal 
tumours increases the risk of metastasis (Haraguchi, 2002). To date CXCL8 has two known 
receptors, CXCR1 and CXCR2. These receptors are known broadly as G-protein coupled 
receptors (GPCR). Recently GPCR antagonists have been developed which can block the 
biological effects of GPCR signalling. [D-Arg1, D-Trp5,7,9,Leu11]SP or substance P antagonist 
is a potent GPCR antagonist and has been shown to inhibit small cell lung cancer cell 
proliferation both in vitro and in vivo (Seckl, 1997) and in pancreatic cancer cell proliferation 
in vitro and in vivo (Guha, 2005). The GPCR ligand/receptor interaction has been shown to 
result in neuropeptide-induced Ca2+ mobilisation which increases intra-cellular Ca2+ and 
this proves useful as a marker of GPCR function (Ryder, 2001). A GPCR antagonist has 
previously been shown to prevent GPCR agonist induced increase in Ca2+, DNA synthesis 
and anchorage independent growth in pancreatic cancer cells (Guha, 2005). The role of a 
GPCR antagonist in colon cancer has yet to be established. IL-8 is produced and has been 
shown to be produced by tumour cells and the level of its production correlates directly 
with the metastatic potential of the tumour (Abdollahi, 2003; Bruserud, 2004). 
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5. Immuno-surveillance 
The interaction between cancer cells and the innate and adaptive immune system is 
complex. As described previously, pro-inflammatory cytokines promote tumour growth; 
however the immune system has a means of restricting cancer development through 
immuno-surveillance and immuno-editing. The pro-tumorigenic effect of the inflammatory 
immune response appears generally to be a consequence of the innate immune system, 
whereas the adaptive immune system exerts anti-tumorigenic effects (Karin, 2005).  
Cancer immunosurveillance is a theory formulated in 1957 by Burnet and Thomas, who 
proposed that lymphocytes act as sentinels in recognising and eliminating continuously 
arising transformed cells (Dunn, 2002; Burnet, 1957). Cancer immunosurveillance appears to 
be an important host protection process that inhibits carcinogenesis and maintains regular 
cellular homeostasis (Kim 2007). It has been shown that when mice are deficient in genes 
that encode for cells integral to the adaptive immune response such as T cells, B cells and 
natural killer T  (NKT) cells, tumour incidence and tumour growth are increased 
(Shankaran, 2001). With the aid of additional studies, natural killer cells and T cells now 
appear to be the dominant cells involved in tumour immuno-surveillance. Interestingly, 
interferon-Ǆ (IFN-Ǆ) is produced by both NKT and T cells. Furthermore, IFN-Ǆ is the most 
influential cytokine released by these cells. Recent studies have now shown that mice 
deficient in IFN-Ǆ are more susceptible to spontaneous carcinogenesis (Shankaran, 2001).  
The mechanism involved in the anticancer protective effect of the immune system is 
complex. Generally, it is theorised that cells of the immune system recognise the presence of 
a growing tumour which has undergone stromal remodelling, causing local tissue damage. 
This is followed by the induction of inflammatory signals which recruits natural killer cells, 
NKT cells and macrophages to the tumour site. During this phase, the infiltrating 
lymphocytes such as the natural killer cells and NKT cells are stimulated to produce IFN-Ǆ. 
Newly synthesised IFN-Ǆ then induces tumour death as well as promoting the production 
of chemokines which play an important role in promoting tumour death by blocking the 
formation of new blood vessels.  
Similarly, IL-4 is released in large quantities by NKT cells upon activation and is a key 
regulator in the adaptive immunity. Therapeutic attempts to recruit the immune system to 
curtail cancer growth have now become a keen area of interest. Although, attempts have 
met with limited success thus far, this is the basis of vaccine guided anti-cancer therapy 
which is a rapidly progressing area of research (Dranoff, 2004).   
It is clear that elements of the immune system can restrict tumour growth. However, as 
discussed previously pro-inflammatory cytokine release initiated by the immune system can 
also promote tumour growth. Therefore, the immune system appears to have the effect of a 
double edged sword on cancer growth. If we had full understanding and control of these 
pathways, this could potentially lead to successful cures for cancer.  
5.1 Vaccines 
Recently vaccines have been developed to take advantage of the role played by the immune 
system in cancer. The discovery of tumour associated antigens (TAA) expressed by 
colorectal carcinoma as well as recent advances in tumour immunology are providing new 
focus to develop biologically targeted immunotherapeutic strategies. It has been reported 
that immuno-deficient animals as well as humans, e.g. transplant patients, are at greater risk 
of developing malignancy (Penn, 2000). It has also been reported that cytotoxic T 
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lymphocytes (CTL) and antibodies specific for TAA have been demonstrated in patients 
with cancers including colorectal cancer (Nagorsen, 2000). Therefore there is an ideal niche 
in cancer treatment for an active specific immunotherapy. Previously identified or 
undefined TAAs can be administered to cancer patients in order to cause a systemic 
immune response which will lead to malignant cell destruction (Rosenberg, 2001). 
Despite the huge amount of evidence and theoretical potential of this treatment strategy, the 
clinical results are limited to date. There is evidence to support the tumouricidal effects of 
active specific immunotherapy however it appears cancer cells are able to survive the 
tumouricidal effects as the disease progresses. This phenomenon has become known as 
‘tumour immune escape’. Several mechanisms have been proposed as to how this 
phenomenon occurs. One body of evidence shows evidence that cancer genetic instability 
leads to TAA/HLA downregulation as well as to disruption of the TAA 
processing/presenting machinery which then allows malignant cells to evade the 
surveillance of immune sentinels (Seliger, 2001; Yang, 2003). Another proposed mechanism 
lies in the ability of cancer cells to produce immunosuppressive cytokines e.g. IL-10, and 
thus counteract the immune system response (Mocellin, 2001; Walker, 1997). The challenge 
for tumour immunologists currently is to overcome this ‘tumour immune escape’ and 
increase the proportion of patients mounting an immune response and increase the rate of 
responses from the targeted tumour. 
The role of macrophages in the development of colorectal cancer is controversial. One study 
demonstrated that increased numbers of macrophages in all areas of the tumour correlated 
with an advanced tumour stage (Bailey, 2007). On the other hand Forssell et al showed that 
the presence of macrophages positively influenced prognosis in colorectal cancer (Forssell, 
2007).  Another group demonstrated that macrophages have the ability to inhibit or 
stimulate tumour growth according to their polarisation and state of activation (Mantovani, 
2005). This group showed that M1-polarised macrophages activated by IFNǄ and bacterial 
products like LPS display tumouricidal effects whereas M2 macrophages differentiated in 
the presence of Th2 cytokines, IL-4, IL-13 or IL-10, have the opposite effect. These 
macrophages favour tumour cell proliferation and stimulate tumour progression and 
tumour invasion. These studies are crucial in demonstrating the important role that 
inflammatory mediators such as chemokines and cytokines play in the establishment of the 
tumour microenvironment. The tumorgenicity of proinflammatory mediators such as 
interleukin-6 and tumour necrosis factor-ǂ (TNFǂ) was shown by Coussens et al (Coussens, 
2002). 
6. Surgery, inflammation and tumourigenesis 
At present, the only recognised curative treatment for cancer is surgery. As a result, surgery 
is the mainstay treatment for tumours.  However, surgery is not indicated for all patients 
with a cancer diagnosis. Surgery is only indicated in these patients if the cancer has not 
dissipated and spread to distant organs. In fact, surgery in these patients worsens outcome 
and survival. This begs the question, is surgery tumorigenic? Numerous studies have 
examined the role of surgery itself on tumour growth. Interestingly, cancer surgery in the 
presence of micrometastases increases metastatic burden and enhances peri-operative 
tumour growth (Pigeon, 1999; MS, 1997; Coffey, 2002). The presence of undetected micro-
metastases is thought to be largely responsible for these recurrences. Cancer patients often 
harbour micrometastases which are undetectable at the time of surgery. Surgical 
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intervention in these patients is thought not only to accelerate their progression but also to 
be responsible for activating dormant micrometastases that may have remained inactive in 
the absence of surgery. In addition, the extent of the surgery is proportional to the post-
operative recurrence rate. This is evidenced by the meta-analyses that show that minimally 
invasive surgery is more effective than open surgery in improving tumour recurrence, and 
cancer-related survival (Hensler, 1997), although equally studies exist that do not support 
this idea (Jayne, 2010). Considering surgery is the only curative treatment of solid tumours, 
this knowledge has prompted efforts to understand this undesired effect of surgery. It is 
hoped that this understanding will eventually help develop therapeutic treatments that may 
attenuate or eliminate this unwelcome consequence of surgery. 
6.1 Mechanisms of surgery induced tumourigenesis 
Considering what is already known concerning the role of inflammation in tumourigenesis, 
it is not surprising that surgery is tumorigenic. Surgery confers a traumatic insult to the 
body which like all traumas induce a potent pro-inflammatory response. Surgery is 
followed by a biologic period of repair to help restore homeostasis. It induces an early 
hyper-inflammatory response, which is characterised by pro-inflammatory TNF-ǂ, IL-1 and 
IL-6 cytokine release (Walker, 1999) and neutrophil activation (Hensler, 1997). Several of 
these cytokines have been shown to potentiate tumour growth (Coussens, 2004). The 
massive and continuous IL-6 release subsequently accounts for the up-regulation of major 
anti-inflammatory mediators, such as PGE2, IL-10, and TGF-ß (Walker 1999). The magnitude 
and duration of this hyper-inflammatory response is proportional to the severity of the 
trauma which may explain how laparoscopic versus open surgery may result in lower 
tumour recurrence (Colacchio, 1994; Baigrie, 1992). Following surgery, angiogenesis is also 
stimulated as the body initiates a period of healing and biological repair. Pro-angiogenic 
substances such as VEGF become elevated post-operatively. Moreover, anti-angiogenic 
substances such as endostatin and angiostatin are not detectable in the serum shortly after 
tumour excision (Li, 2001; Holmgren 1995; O'Reilly, 1994). This incites the formation of 
capillaries and new blood vessels not only to the areas of tissue insult but also to all parts of 
the body including areas of residual metastatic disease which promotes tumour growth. 
Furthermore, surgery also influences immune system function. Immuno-suppression is a 
feature of the post-operative stress response and is also associated with anaesthesia, blood 
transfusion and the release of acute-phase proteins (Lee, 1977). The immune system appears 
to be an important regulator in identifying and eliminating any abnormal cells with 
cancerous potential. Hence, any disruption of immune function as a result of surgery can 
also lead to potentiating tumour growth. Interestingly, this immuno-suppression is greater 
dependent on the extent of surgery (Da Costa, 1998; Da Costa, 1999). The 
immunosuppressive effects of surgery can last anywhere from between 4 to 14 days 
depending on the size of surgical trauma induced but peaks day three post-operatively in 
most cases. Likewise, this may explain why laparoscopic versus open surgery in colon 
cancer patients confers a greater survival advantage, although the evidence supporting this 
is not equivocal. 
Endotoxaemia also occurs following surgery involving bowel manipulation. Endotoxin, a 
potent inflammatory mediator, is a component on the wall of Gram negative bacteria often 
found in the lumen of the gastrointestinal system. Upon manipulation, endotoxin or LPS 
translocates across the intestinal lumen and enters the circulation. Endotoxaemia further 
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potentiates the hyper-inflammatory response following surgery such as colorectal cancer 
resection. One study examined the effect of endotoxin administration on a murine breast 
cancer model (Pigeon, 1999).  Interestingly, they found enhanced metastatic growth in the 
endotoxin treated group compared to controls.  In a later study the same group found that 
endotoxin-induced metastatic growth was associated with increased angiogenesis, vascular 
permeability and tumour cell invasion and migration (Harmey, 2002).  Therefore, this is 
another potential mechanism of surgically induced tumour growth especially in regard to 
colorectal cancer operations. In addition, the actual manipulation of the tumour during 
surgery results in the dissemination of tumour cells into the circulation. These tumour cells 
can potentially seed in distant sites throughout the body facilitating metastatic spread. 
Surgeons will make efforts to minimise tumour manipulation intra-operatively to minimise 
this potential. 
Peri-operative tumour growth appears to significantly impact on tumour recurrence 
following “curative” surgery. Following a deeper understanding of this mechanism, 
therapeutic efforts are now being sought. Peri-operative immunomodulators such as IL-2, 
known to abrogate the immune changes that follow excisional cancer surgery, are being 
investigated as potential peri-operative treatments showing promising initial results (Den 
Otter, 1996). Even current chemotherapeutic regimes known to induce cell death in rapidly 
dividing cells have been given immediately post-operatively resulting in increased long-
term survival. However, most of these treatments are limited by their toxicities as tissue and 
wound healing are essential in the immediate post-operative period.  
7. Conclusion 
Overall, our understanding of the relationship between inflammation and cancer has 
improved greatly since Virchow first made his observation over 150 years ago. The 
unravelling of signalling pathways shared by cancer and inflammation will provide the 
focus for future cancer treatment strategies.  
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